Journal September 16, 2026 6 min read

MOTS-c vs NAD+: What the Research Actually Compares

A comparison of the published research on MOTS-c and NAD+, covering what each is, what studies measured, where evidence is stronger, and what remains unknown.

peptides-pro Editorial

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a mitochondrial-derived peptide encoded within the 12S rRNA gene of mitochondrial DNA. It is an amphipathic and cationic peptide with direct antibacterial and immunomodulatory functions, consistent with known host defense peptides [1]. Its sequence is Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg, and it is also referred to as a mitochondrial-derived microprotein or mitokine [5][11].

NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme involved in redox reactions and cellular energy metabolism. It is not a peptide; it is a small molecule. The research on NAD+ as a supplement centres on its absorption, safety, and efficacy in healthy adults, with a primary outcome of change in whole blood NAD+ levels [2].

The work on MOTS-c centres on metabolic and inflammatory pathways, including AMPK signalling, the NLRP3 inflammasome, and Nrf2 activation [3][5]. The work on NAD+ centres on its role as a substrate for enzymes and its bioavailability when administered orally [2].

Research Studies

MOTS-c and host defense in bacterial infection models

MOTS-c was identified as a mitochondrial-encoded host defense peptide with direct antibacterial and immunomodulatory functions. In laboratory studies, MOTS-c targeted Escherichia coli and other pathogens, consistent with the chemistry and functions of known host defense peptides [1]. This work established that the mitochondrial genome can encode active immune factors, a function previously thought to be exclusively nuclear-encoded [1].

MOTS-c and systemic and cardiac inflammasome activation in diabetic rats

In a high-fat diet and streptozotocin-induced type 2 diabetes rat model, MOTS-c treatment significantly reduced fasting blood glucose and circulating C-reactive protein levels, while selectively modulating plasma inflammatory markers. The study investigated NLRP3 inflammasome activity and reported that MOTS-c suppressed systemic and cardiac inflammasome activation [3].

MOTS-c and circulating levels in Hashimoto's thyroiditis

A cross-sectional study compared 90 patients diagnosed with Hashimoto's thyroiditis to age- and sex-matched healthy controls. The study aimed to investigate the association between circulating MOTS-c levels and Hashimoto's thyroiditis, and to explore its potential role in thyroid autoimmunity and metabolic regulation. Reduced circulating MOTS-c levels were observed in Hashimoto's thyroiditis, reflecting integrated autoimmune and metabolic dysregulation [4].

MOTS-c and engineered analogues in radiation-induced lung injury

Because wild-type MOTS-c has poor membrane permeability due to its high polarity, researchers engineered R13A-MOTS-c by substituting the polar arginine at position 13 with alanine. This modification increased the peptide's hydrophobicity index from -0.938 to -0.544, improving cellular uptake. Functional uptake assays, including competition with canonical LAT1 substrates (leucine, BCH) and LAT1 knockdown experiments, confirmed that R13A-MOTS-c enters cells via LAT1-mediated delivery. In this model, R13A-MOTS-c attenuated radiation-induced lung injury via Nrf2 activation and mitochondrial protection [5].

MOTS-c and atrial fibrillation in human tissue and mouse models

A study analysed human atrial tissues using public GEO data, immunohistochemistry, and immunofluorescence, and evaluated therapeutic potential in an AngII-induced mouse model and primary cardiac cells. The study found that humanin and MOTS-c expression was altered in atrial fibrillation, and that both peptides attenuated atrial fibrillation by suppressing fibrosis and mitochondrial dysfunction [6].

MOTS-c and myocardial ischemia-reperfusion injury in acute myocardial infarction patients

A cross-sectional study enrolled 72 acute myocardial infarction patients undergoing percutaneous coronary intervention, divided into MIRI (n=34) and non-MIRI (n=38) groups. Clinical data and MOTS-c levels in peripheral serum and intracoronary blood were analysed. The study investigated the relationship between serum MOTS-c levels and myocardial ischemia-reperfusion injury [7].

MOTS-c and polycystic ovary syndrome in adolescents

A study investigated differences in MOTS-c levels between adolescents diagnosed with polycystic ovary syndrome and those without, as well as associations with metabolic parameters. The association between the MOTS-c gene polymorphism m.1382A>C and serum MOTS-c levels was also evaluated. The polymorphism has been linked to an increased risk of type 2 diabetes in men [8].

NAD+ and oral supplementation in healthy adults

A clinical trial is assessing the absorption, safety, and efficacy of an oral NAD+ supplement in healthy adults. The main question is the change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo groups. Participants will complete questionnaires, provide blood samples, consume either the NAD+ supplement or a placebo for 55 days, and have endothelial function evaluated [2].

MOTS-c and sepsis-induced cardiomyopathy (reference only)

A review reports that sepsis-induced cardiomyopathy is characterized by inflammatory dysregulation, mitochondrial dysfunction, metabolic disturbance, and changes in the myocardial microenvironment, and discusses MOTS-c in this context [9].

MOTS-c and mesenchymal stromal cell function (reference only)

A study reports that MOTS-c activates metabolic signalling but blunts reparative function in human mesenchymal stromal cells, and that obesity compromises MSC metabolism and reparative capacity [10].

MOTS-c and inflammatory lung diseases (reference only)

A review reports that MOTS-c is a mitochondrial-derived microprotein with intracrine, paracrine, and endocrine effects, and that growing evidence indicates it modulates oxidative stress and inflammation in inflammatory lung diseases [11].

MOTS-c and cardiac ischemia-reperfusion injury (reference only)

A study reports that MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia-reperfusion injury [12].

Comparison of Evidence

Feature	MOTS-c	NAD+
Class	Mitochondrial-derived peptide (mitokine)	Dinucleotide coenzyme
Identifiers	Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg [5]	Not provided in evidence
Primary research focus	Metabolic and inflammatory pathways, host defense, tissue protection [1][3][5][6][7][8]	Absorption, safety, and efficacy as an oral supplement [2]
Study types	Preclinical models (rat, mouse, cell), cross-sectional human studies [3][4][5][6][7][8]	Clinical trial in healthy adults [2]
Measured outcomes	Blood glucose, CRP, inflammasome activity, circulating levels, tissue expression [3][4][6][7][8]	Whole blood NAD+ levels, endothelial function [2]
Human interventional data	Not reported in evidence	Ongoing trial [2]

The evidence for MOTS-c is broader in terms of mechanisms and disease models, but it is largely preclinical or cross-sectional. The evidence for NAD+ as a supplement is narrower in scope but includes a clinical trial design in healthy adults [2]. Neither compound has published evidence in the provided sources that establishes a clinical benefit for any indication.

What Is Not Known

For MOTS-c, the evidence does not include human interventional trials. The relationship between circulating MOTS-c levels and disease states is associative, not causal [4][7][8]. The therapeutic potential of engineered analogues such as R13A-MOTS-c has been tested only in preclinical models [5]. The role of MOTS-c in sepsis-induced cardiomyopathy, mesenchymal stromal cell function, inflammatory lung diseases, and cardiac ischemia-reperfusion injury is reported in reference-only sources and does not constitute established clinical evidence [9][10][11][12].

For NAD+, the evidence does not yet report results from the clinical trial; only the trial design and objectives are available [2]. The evidence does not provide data on long-term safety, efficacy for any health outcome, or comparison with other NAD+ precursors.

No source in the evidence compares MOTS-c and NAD+ directly. The two compounds are studied in different research contexts and for different purposes.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research use only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.